David M. Rubenstein - 30 Apr 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, As Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
30 Apr 2025
Net transactions value
$0
Form type
4
Filing time
01 May 2025, 16:34:05 UTC
Previous filing
07 Aug 2024
Next filing
06 Aug 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +677 677 30 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -677 -100% $0.000000 0 30 Apr 2025 Common Stock 677 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Award $0 +12,756 $0.000000 12,756 30 Apr 2025 Common Stock 12,756 $28.54 Direct F3
transaction MRNA Restricted Stock Units Award $0 +8,116 $0.000000 8,116 30 Apr 2025 Common Stock 8,116 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The shares subject to this restricted stock unit award vested in full on April 30, 2025.
F3 This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
F4 The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.